See Supplemental Patient Information
- Use of ACE inhibitor during the second and third trimesters of pregnancy is associated with fetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, and reversible or irreversible renal failure, which may cause fetal/neonatal morbidity and mortality
- Discontinue therapy to the earliest on detection of pregnancy. Drugs acting directly on the renin-angiotensin system are associated with injury and death to the developing fetus [US Black Box warning]
- Hypersensitivity reactions such as anaphylactic reactions and angioedema of the face, extremities, lips, tongue, glottis and/or larynx requiring hospitalization and intubation may occur in patients treated with this drug. This may occur at any time during treatment and may occur in patients with and without a history of angioedema with ACE inhibitors or angiotensin receptor antagonists. Airway obstruction may occur and can be fatal if angioedema involves the throat, tongue, glottis or larynx, or if the patient has a history of upper respiratory surgery. Immediately discontinue this drug in patients who develop angioedema, and do not readminister
- Symptomatic hypotension may occur after starting the therapy in patients with marked volume depletion, hence correct the volume or salt depletion prior to administration
- Periodically monitor serum electrolytes in patients with severe renal impairment to detect possible electrolyte imbalances
- Exercise caution if used concomitantly with ACE inhibitors in diabetic patients, potassium-sparing diuretics, potassium supplements, and other drugs that increase serum potassium levels; periodically monitor electrolytes and renal function in these patients
Cautions: Use cautiously in
- Renal artery stenosis
- History of renal disease
- Hyponatremia
Supplemental Patient Information
- Apprise female patients of childbearing age about the potential hazard to the fetus; advise patients to promptly report their pregnancies as early as possible
- Caution patients about the possibility of lightheadedness, especially during the first days of therapy
- Advise patients not to use potassium supplements or salt substitutes containing potassium during therapy
- Advise patients to establish a routine pattern for taking aliskiren with regard to meals
Pregnancy Category:C (first trimester) / D (second and third trimesters)
Breastfeeding: Manufacturer recommends discontinuation of nursing or therapy, after analyzing the risk and benefit ratio in nursing mothers.
Pricing data from www.DrugStore.com in U.S.A.
- Tekturna 300 MG TABS [Bottle] (NOVARTIS)
30 mg = $123
90 mg = $349.96 - Tekturna 150 MG TABS [Bottle] (NOVARTIS)
30 mg = $97.92
90 mg = $277.43
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
